Clinical Trials Logo

Clinical Trial Summary

This study investigates gene abnormalities in Primary Immune Deficiency(PID) with a goal of improving the diagnosis and treatment of patients.

The specific disorders include:

1. X linked hyper IgM Syndrome which is caused by an abnormality in the CD40L gene.

2. NEMO associated immune deficiency which is caused by an abnormality in a gene called NEMO.

3. Common variable immunodeficiency (CVID) which has an unknown genetic basis.

4. Other disorders of immunoglobulin production.

This study will:

1. Better characterize the clinical features of CD40 L deficiency and NEMO associated immune deficiency and other related primary immune deficiency syndromes.

2. Determine the frequency of CD40 L and Nemo abnormalities.

3. Determine whether particular abnormalities in these genes are associated with more of less severe illness or with specific symptoms.

4. Explore the basic mechanism by which these altered genes cause immune dysfunction.

5. Identify other genes causing low immune globulin levels and related primary immune deficient states.


Clinical Trial Description

This protocol is designed to study the genetics and pathophysiology of Hyper-IgM syndrome, NEMO associated immune deficiency, patients with related primary immune deficiency disorders, and the blood relatives of immunodeficient patients. Patients will undergo evaluations that include history/physical, blood sampling, genetic testing, and possible tissue sampling. Among the aims of this protocol are to better understand genetic factors that lead to defects in host defense, and to use modern and evolving methods in molecular and cellular biology to elucidate the pathogenesis of these diseases. A better understanding of primary immunodeficiency could allow for the rational development of novel therapies for such diseases and to benefit future patients, but it might not benefit current patients directly. Routine follow-up may occur every six months - with evaluation and blood sampling. Under some circumstances, we may provide treatment that relates to the immune deficiency. These treatments will follow standard medical practice. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00266513
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Terminated
Phase N/A
Start date December 14, 2005
Completion date July 11, 2013

See also
  Status Clinical Trial Phase
Recruiting NCT05954416 - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Terminated NCT02896387 - Ability of a Molecule (Prima) to Restore Physiological Differentiation in Epithelium Expressing Gene p63
Completed NCT01108770 - Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia N/A
Completed NCT00001211 - Clinical Study of Oral Endosseous Titanium Implants in Edentulous Subjects N/A
Recruiting NCT06330350 - Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
Enrolling by invitation NCT06330324 - Reproductive Options in Inherited Skin Diseases